Table 1.

Demographic	MBSR Group (N=27)	Control Group (N=28)	P Value
Age	46.04 ± 12.80	39.68 ±11.06	0.05*
Gender
Male	15 (15/27, 55.6%)	9 (9/28, 32.1%)	0.14
Female	12 (12/27, 44.4%)	19 (19/28, 67.9%)
Ethnicity/Race
Asian	1 (1/27, 3.7%)	1 (1/28, 3.6%)	0.08
Black or African American	0 (0/27, 0%)	5 (5/28, 17.9%)
White	26 (26/27, 96.3%)	22 (22/28, 78.6%)
Hispanic	3 (3/27, 11.1%)	2 (2/28, 7.1%)
Not Hispanic	24 (24/27, 88.9%)	26 (26/28, 92.9%)
Marital Status
Married	17 (17/27, 63.0%)	12 (12/28, 42.9%)	0.30
Single	8 (8/27, 29.6%)	14 (14/28, 50.0%)
Divorced or Legally separated	2 (2/27, 7.4%)	2 (2/28, 7.1%)
Work Status1
Full time	21 (21/27, 77.8%)	19 (18/28, 64.3%)	0.05*
Part time	2 (2/27, 7.4%)	3 (3/28, 10.7%)
Unemployed, Retired, or Homemaker	2 (2/27, 7.4%)	3 (3/28, 10.7%)
Student	0 (0/27, 0%)	1 (1/28, 3.4%)
Disability	0 (0/27, 0%)	1 (1/28, 3.4%)
Age at diagnosis	38.72 ± 13.55	31.48 ± 9.82	0.03*
Extent of disease2
Left-sided	12 (12/27, 44.4%)	8 (8/28, 28.6%)
Pan-colitis	14 (14/27, 51.9%)	18 (18/28, 64.3%)
Total # of flare-ups	4.3 ± 2.5	5.1 ± 3.5	0.40
Flare-ups in the past year	3.1 ± 4.3	1.8 ± 0.9	0.20
Prednisone Dependent
Yes	11 (11/27, 40.7%)	13 (13/28, 46.4%)	0.70
No	16 (16/27, 59.3%)	15 (15/28, 53.6%)
Current IBD Medications2
None	2 (2/27, 7.4%)	2 (2/28, 7.1%)	0.80
5ASA	22 (22/27, 81.5%)	22 (22/28, 78.6%)
Immunomodulators	7 (7/27, 25.9%)	6 (6/28, 21.4%)
Biologic	4 (4/27, 14.8%)	3 (3/28, 10.7%)
Prednisone (< 5mg)	4 (4/27, 14.8%)	3 (3/28, 10.7%)
Past Prednisone
Yes	18 (18/27, 66.7%)	19 (19/28, 67.9%)	0.90
No	7 (7/27, 25.9%)	7 (7/28, 25.0%)

Values expressed as mean ± standard deviation.

^*p<0.05.

¹Three patients did not identify work status.

²Extent of disease is unknown for three patients (1 in MBSR and 2 in Control).

³Many patients were taking more than one medication, thus totals exceed 100%